Epirubicin
- Generic Name
- Epirubicin
- Brand Names
- Ellence, Pharmorubicin PFS
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29NO11
- CAS Number
- 56420-45-2
- Unique Ingredient Identifier
- 3Z8479ZZ5X
- Background
An anthracycline which is the 4'-epi-isomer of doxorubicin. The compound exerts its antitumor effects by interference with the synthesis and function of DNA.
- Indication
For use as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement following resection of primary breast cancer.
- Associated Conditions
- Breast Cancer, Breast Cancer, Stage II, Breast Cancer, Stage III, Colorectal Cancer, Hormone-Refractory Prostate Cancer, Neoplasm of Stomach, Non-Small Cell Lung Carcinoma, Ovarian Cancer, Papillary transitional cell carcinoma of bladder, Recurrent Superficial Bladder Cancer, Small Cell Lung Cancer (SCLC), Soft Tissue Sarcoma, Carcinoma in situ of urinary bladder
- Associated Therapies
- -
Study Comparing EC-T Verses PCb in the Adjuvant Chemotherapy of Non-triple Negative Breast Cancer
- First Posted Date
- 2019-12-10
- Last Posted Date
- 2020-03-09
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1560
- Registration Number
- NCT04193059
- Locations
- 🇨🇳
Cancer Hospital Affiliated to Fudan University, Shanghai, Shanghai, China
ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC
- Conditions
- Interventions
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-10-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 156
- Registration Number
- NCT04172259
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
Adjuvant 6 Cycles of Docetaxel and Cyclophosphamide or 3 Cycles of Cyclophosphamide/Epirubicin/Fluorouracil Followed by 3 Cycles of Docetaxel Versus 4 Cycles of Epirubicin and Cyclophosphamide Followed by Weekly Paclitaxel in Operable Breast Cancer (MASTER)
- Conditions
- Interventions
- First Posted Date
- 2019-10-15
- Last Posted Date
- 2020-02-26
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 2079
- Registration Number
- NCT04127019
Camrelizumab Combined With AVD in the First-line Treatment for Patients With Advanced Classical Hodgkin's Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-26
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT04067037
- Locations
- 🇨🇳
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, Zhengzhou, Henan, China
A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2019-08-20
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 54
- Registration Number
- NCT04061772
- Locations
- 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China
Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)
- Conditions
- Interventions
- First Posted Date
- 2019-07-24
- Last Posted Date
- 2020-04-24
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 647
- Registration Number
- NCT04031703
Improving Pre-operative Systemic Therapy for Human Epidermal Growth Factor Receptor 2 (HER2) Amplified Breast Cancer
- First Posted Date
- 2019-03-28
- Last Posted Date
- 2021-09-23
- Lead Sponsor
- Renske Altena
- Target Recruit Count
- 6
- Registration Number
- NCT03894007
- Locations
- 🇸🇪
Sahlgrenska universitetssjukhuset, Göteborg, Sweden
🇸🇪Skånes universitetssjukhus, Malmö, Sweden
🇸🇪Länssjukhuset Sundsvall, Sundsvall, Sweden
Combination Therapy of Anthracyclines for Children With Nephroblastoma
- Conditions
- Interventions
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2019-03-27
- Lead Sponsor
- Shengjing Hospital
- Target Recruit Count
- 120
- Registration Number
- NCT03892330
- Locations
- 🇨🇳
Shenjing Hospital, Shenyang, Liaoning, China
The Trial Comparing Dose-dense AC-T With TP as Adjuvant Therapy for TNBC With Homologous Recombination Repair Deficiency
- Conditions
- Interventions
- First Posted Date
- 2019-03-15
- Last Posted Date
- 2019-03-21
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 200
- Registration Number
- NCT03876886
- Locations
- 🇨🇳
National Cancer Center, Cancer Hospital/Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China
The Combination of Palbociclib With ddEC-P as Neoadjuvant Therapy in Triple Negative Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2018-11-28
- Last Posted Date
- 2018-12-07
- Lead Sponsor
- Zhejiang Cancer Hospital
- Target Recruit Count
- 100
- Registration Number
- NCT03756090
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.